Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies

Article Details

Authors
Ana Rosa Jurado López MD, PhD, Francisca Molero Rodríguez MD

Article Type
Case Report

DOI
10.7573/dic.2020-3-8

Related Articles

Article Page

Abstract

The pathophysiological changes associated with hypoestrogenism of menopause, a condition known as genitourinary syndrome of menopause, are responsible for the hallmark symptoms of vulvovaginal atrophy (VVA), namely dyspareunia secondary to vaginal dryness. Many postmenopausal women with VVA find sexual relations to be challenging or impossible. Ospemifene has estrogen-like effects on the vaginal epithelium, and is indicated to treat moderate-to-severe symptomatic VVA (Europe) or moderate-to-severe symptomatic dyspareunia and vaginal dryness (United States) in postmenopausal women. The case studies presented in this article follow the progress of two women who began treatment with ospemifene for the main presenting symptom of dyspareunia. Both women had concerns about the impact of their symptomatology on new relationships. The patient in case 1 experienced relevant improvement within 3 months of treatment start and, by 1 year, dyspareunia was absent. Vaginal lubricants were no longer required. The patient in case 2 experienced relevant improvement within 4 weeks of starting ospemifene. At 15 months, with the use of a lubricant for vaginal penetration, she could enjoy sexual intercourse without pain. At the time of writing, she had been receiving ospemifene continuously for more than 2 years with effective symptom relief and good tolerability.

Keywords: ospemifene, sexual dysfunction, vulvar and vaginal atrophy.

Citation: Jurado López AR, Molero Rodríguez F. Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies. Drugs in Context 2020; 9: 2020-3-8. DOI: 10.7573/dic.2020-3-8

Contributions: All authors contributed equally to the preparation of this case report. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: Dr. Jurado López reports personal fees from Shionogi, outside the submitted work. Dr. Molero Rodríguez reports personal fees from Shionogi, outside the submitted work. The authors have also provided scientific support to Shionogi Spain by lecturing and/or taking part in Advisory Board meetings organized by Shionogi (Madrid, Spain). The authors’ time was compensated by Shionogi Spain according to local codes of practice. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/06/dic.2020-3-8-COI.pdf

Acknowledgements: Medical writing assistance was provided by Jon Monk and Kerry Dechant on behalf of Content Ed Net (Madrid, Spain). This article forms part of a Special Issue. All authors contributed to developing this Special Issue by sharing their experience with the benefit of patients in mind. The publication is expected to benefit gynecologists in their daily clinical practice by increasing knowledge and expertise.

Funding declaration: Medical writing assistance was funded by Shionogi (Madrid, Spain). This article forms part of a Special Issue funded by Shionogi (Madrid, Spain).

Copyright: Copyright © 2020 Jurado López AR, Molero Rodríguez F. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2020 Jurado López AR, Molero Rodríguez F. https://doi.org/10.7573/dic.2020-3-8. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/experience-with-ospemifene-in-patients-with-vulvar-and-vaginal-atrophy-and-associated-sexual-dysfunction:-case-studies/

Correspondence: Ana Rosa Jurado López, Instituto Europeo de Sexología, Elviria Medical Centre, Av. de las Cumbres, s/n, Edf. Elviria Business Centre, Local B3, 29604 Marbella, Málaga, Spain. anarosajuradolopez@gmail.com

Provenance: submitted; externally peer reviewed.

Submitted: 20 March 2020; Peer review comments to author: 16 April 2020; Revised manuscript received: 20 May 2020;
Accepted: 21 May 2020; Publication date: 1 July 2020.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF